Business Context and Reporting Period
Company: Diodes Incorporated
Filing Type: Form 8-K (Current Report)
Date of Report: October 29, 2008 (Earliest event reported)
Reporting Period: Events occurring between October 29, 2008, and November 4, 2008.
Context: The filing details a settlement agreement with UBS AG and affiliates regarding the Company's illiquid auction rate securities (ARS) portfolio, aimed at providing liquidity and resolving financial obligations.
Key Financial Metrics and Obligations
- ARS Portfolio Value: $320.7 million.
- Existing Margin Loan: $165.0 million (replaced by new arrangement).
- New Credit Facility: "No Net Cost Loan" up to 75% of the market value of pledged ARS.
- Reimbursement: Approximately $800,000 to cover the difference between the cost of the existing margin loan and interest received on the ARS portfolio.
- Interest Rate: Interest paid on the new loan will not exceed interest received on the pledged ARS.
Material Changes and Agreements
The Company entered into a material definitive agreement with UBS to address liquidity issues surrounding its ARS holdings. Key changes include:
- Sale Option: UBS granted Diodes the right to sell the $320.7 million ARS portfolio at 100% par value between June 30, 2010, and July 2, 2012.
- Loan Restructuring: The existing $165.0 million margin loan was replaced by a new credit line secured by the ARS portfolio.
- Release of Claims: Diodes released UBS from all claims except those for consequential damages related to ARS sales.
- UBS Rights: UBS retains the right to sell the ARS at par without notice, provided proceeds are paid to Diodes within one day of settlement.
Outlook, Risks, and Contingencies
- Liquidity Risk: The new credit line is subject to collateral maintenance requirements. UBS Bank may demand full or partial payment at its sole option and without cause.
- Termination Risk: UBS Bank may terminate and cancel the credit line at any time in its discretion.
- Contingency Plan: If UBS demands payment and alternative financing cannot be established, a UBS entity agrees to purchase the pledged ARS at par value.
- Collateral Constraints: Advances will not be made against the fair market or par value of the collateral unless additional collateral or assurances are provided.
Investor Verification Checklist
- Verify the current market value of the $320.7 million ARS portfolio to assess the actual borrowing capacity under the 75% limit.
- Review the specific terms of the "No Net Cost Loan" in Exhibit 99.2 regarding collateral maintenance triggers.
- Confirm the timeline and conditions for the right to sell ARS at par value between 2010 and 2012.
- Assess the impact of the $800,000 reimbursement on the current quarter's financial statements.
- Monitor for any future demands for repayment by UBS Bank under the discretionary terms of the agreement.